Design of oral drug delivery systems – Past,present and future

Abstract

This paper reviews the past and the present thinking about peroral delivery research and development and how future approaches may be significantly different, both qualitatively and quantitatively. The future should involve the use of comprehensive models capable of incorporating physico-chemical data and biological information such as gastrointestinal flow, how and where drug absorption occurs, and whether and where metabolism of the drug occurs during gastrointestinal transit. Special challenges would involve the use of such models in research protocols in the optimization of drug delivery systems.     

Preface for buccal drug delivery theme issue

During the past years, buccal drug delivery has attracted the attention of researchers looking for alternative delivery routes of administration. As an alternative to oral drug delivery, the buccal mucosal route avoids the passage through the acidic gastric environment, intestinal and bacterial enzymatic activity, absorption issues associated with the intestinal epithelium (e.g. P-glycoprotein efflux), and the first pass metabolism of the liver. Therefore, the buccal route could be a good delivery route for macromolecules and other drugs not compatible with the gastrointestinal tract environment. This “Buccal Drug Delivery” special edition of Drug Development and Industrial Pharmacy aims to bring together a range of different aspects relevant to the growing field of buccal drug delivery. The special edition includes thorough reviews of the literature, as well as original research articles touching on most prominent features related to buccal drug delivery systems, such as the move toward the use of nanotechnology in different ways to facilitate buccal drug delivery with the potential to prompt future product developments.     

可降解医用高分子材料降解建模研究现状

可降解医用高分子材料降解过程复杂,致其医用研究尚处于＂试错＂阶段。文中就降解医用高分子材料的降解建模研究现状展开讨论,针对建模相对比较成熟的药物缓释系统介绍了机理论模型的非蒙特卡洛模型和蒙特卡洛模型及元胞自动机模型;分析了药物缓释系统、组织工程支架降解建模中建模方法的思路与存在的问题;归纳了当前的建模或从微观或从宏观角...     

Oral drug delivery platforms for biomedical applications

Oral administration is perhaps the most commonly used and acceptable route for drug delivery to patients, mainly due to its non-invasiveness, simplicity, and versatility. Conventional delivery media such as tablets or capsule-based formulations, however, could result in low drug bioavailability and insufficient therapeutic efficiency, especially for delivering biologics (e.g., peptide, protein, antibody, nucleic acid). Therefore, with the advancement of material science and micro-/nano-fabrication techniques, various carriers have been developed to protect drugs and improve their absorption in the gastrointestinal (GI) tract. Herein, we first summarized various types of drug molecules being used for oral administration. Then we discussed the major physiological barriers (including various biochemical, mucosal diffusion, and cellular permeation barriers) that hinder drug transportation and absorption, as well as the main targeting regions in the GI tract. On this basis, we reviewed recently emerged oral drug delivery platforms and discussed their widely investigated biomedical applications. Finally, we present future perspectives for materials science-enabled oral drug delivery platforms, and potential challenges for clinical translation.     

Tablet Excipients to the Year 2001: A Look into the Crystal Ball

The future for tablet excipients is reviewed from a number of viewpoints: new materials, formulation development, quality, regulatory aspects, logistics, and production. The field of excipients is changing rapidly in response to economic, regulatory, and scientific pressures. As our understanding of drug delivery improves, so will the demands we place on excipients and on their quality, both chemical and functional. In order to fully optimize drug delivery systems, a better understanding of excipients and their properties and limitations is required. The materials science approach to the study of excipients will help to increase our understanding of excipients and how best to use them. But excipients are only one part of the very complex mechanism whereby new medicinal products are brought to the marketplace. It is important that the processes of formulation design and development are properly integrated to obtain optimized drug delivery systems as early as possible. Developments in related fields such as manufacturing technology, logistics, and analytical techniques will also influence the field of excipients.     

Recent advances in ocular drug delivery

Amongst the various routes of drug delivery, the field of ocular drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientist. Recent research has focused on the characteristic advantages and limitations of the various drug delivery systems, and further research will be required before the ideal system can be developed. Administration of drugs to the ocular region with conventional delivery systems leads to short contact time of the formulations on the epithelium and fast elimination of drugs. This transient residence time involves poor bioavailability of drugs which can be explained by the tear production, non-productive absorption and impermeability of corneal epithelium. Anatomy of the eye is shortly presented and is connected with ophthalmic delivery and bioavailability of drugs. In the present update on ocular dosage forms, chemical delivery systems such as prodrugs, the use of cyclodextrins to increase solubility of various drugs, the concept of penetration enhancers and other ocular drug delivery systems such as polymeric gels, bioadhesive hydrogels, in-situ forming gels with temperature-, pH-, or osmotically induced gelation, combination of polymers and colloidal systems such as liposomes, niosomes, cubosomes, microemulsions, nanoemulsions and nanoparticles are discussed. Novel ophthalmic delivery systems propose the use of many excipients to increase the viscosity or the bioadhesion of the product. New formulations like gels or colloidal systems have been tested with numerous active substances by in vitro and in vivo studies. Sustained drug release and increase in drug bioavailability have been obtained, offering the promise of innovation in drug delivery systems for ocular administration. Combining different properties of pharmaceutical formulations appears to offer a genuine synergy in bioavailability and sustained release. Promising results are obtained with colloidal systems which present very comfortable conditions of use and prolonged action.     

分离膜表面接枝制备刺激响应性膜研究进展

刺激响应性分离膜的制备及研究是近年来的热点,其在生物传感器、选择性分离、药物可控释放等领域具有广阔的应用前景。文中综述了等离子处理引发接枝,紫外光引发接枝,化学热引发接枝和可控活性接枝等四种主要的接枝方法在高分子分离膜表面的接枝改性研究进展,主要围绕具有刺激响应性功能的分离膜的制备研究进行介绍,对存在的问题进行了讨论,并阐述了刺激响应性分离膜的发展方向。     

多孔碳纳米材料构建抗肿瘤药物靶向传递系统的研究进展

抗肿瘤药物靶向传递系统是提高传统化疗药物疗效, 并降低其毒副作用的重要手段。以多孔碳纳米材料为药物载体, 根据肿瘤组织微环境特点, 构建抗肿瘤药物靶向传递系统是实现靶向治疗方案的有效方式。本文围绕基于多孔碳纳米材料的抗肿瘤药物靶向传递系统的构建及应用进行综述, 描述了多孔碳纳米材料适宜载药的设计、合成及功能化修饰; 通过理论与实例相结合的方式, 介绍了提高多孔碳纳米材料载药量和实现联合给药的有效策略; 从内源和外源性敏感刺激的角度, 重点分析了多孔碳纳米材料基于肿瘤微环境构建的靶向传递系统的机制和应用; 阐述了多孔碳纳米材料作为抗肿瘤药物载体面临的生物相容性和生物降解性的问题, 并分析了可能的解决途径; 展望了多孔碳纳米材料在构建肿瘤药物靶向传递系统应用中的前景及发展方向, 为研发靶向、可控的抗肿瘤药物传递系统提供了理论依据和例证支持。     

Strategies to improve micelle stability for drug delivery

Micelles have been studied as drug delivery carriers for decades. Their use can potentially result in high drug accumulation at the target site through the enhanced permeability and retention effect. Nevertheless, the lack of stability of micelles in the physiological environment limits their efficacy as a drug carrier. In particular, micelles tend to disassociate and prematurely release the encapsulated drugs, lowering delivery efficacy and creating toxicity concerns. Many efforts to enhance the stability of micelles have focused mainly on decreasing the critical micelle forming concentration and improving blood circulation. Herein, we review different strategies including crosslinking and non-crosslinking approaches designed to stabilize micelles and offer perspectives on future research directions.     

Microemulsions as a Surrogate Carrier for Dermal Drug Delivery

Microemulsions are isotropic, thermodynamically stable transparent (or translucent) systems of oil, water, and surfactant, frequently in combination with a cosurfactant with a droplet size usually in the range of 20–200 nm. Since their discovery, they have attained increasing significance both in basic research and in industry. Due to their distinct advantages such as enhanced drug solubility, thermodynamic stability, facile preparation, and low cost, uses and applications of microemulsions have been numerous. Recently, there is a surge in the exploration of microemulsion for transdermal drug delivery for their ability to incorporate both hydrophilic (5-fluorouracil, apomorphine hydrochloride, diphenhydramine hydrochloride, tetracaine hydrochloride, and methotrexate) and lipophilic drugs (estradiol, finasteride, ketoprofen, meloxicam, felodipine, and triptolide) and enhance their permeation. Very low surface tension in conjunction with enormous increase in the interfacial area due to nanosized droplets of the microemulsion influences the drug permeation across the skin. A large number of oils and surfactants are available, which can be used as components of microemulsion systems for transdermal delivery but their toxicity, irritation potential, and unclear mechanism of action limit their use. Besides surfactants, oils can also act as penetration enhancers (oleic acid, linoleic acid, isopropyl myristate, isopropyl palmitate, etc.). The transdermal drug delivery potential of microemulsions is dependent not only on the applied constituents of the vehicle but also drastically on the composition/internal structure of the phases which may promote or hamper the drug distribution in the vehicles. This article explores microemulsion as transdermal drug delivery vehicles with emphasis on components selection for enhanced drug permeation and skin tolerability of these systems and further future directions.     

Ocular Preparations: The Formulation Approach

ABSTRACT

The main aim of pharmacotherapeutics is the attainment of an effective drug concentration at the intended site of action for a sufficient period of time to elicit the response. A major problem being faced in ocular therapeutics is the attainment of an optimal concentration at the site of action. Poor bioavailability of drugs from ocular dosage forms is mainly due to the tear production, non-productive absorption, transient residence time, and impermeability of corneal epithelium. This article reviews: the barriers that decrease the bioavailability of an ophthalmic drug; the objectives to be considered in producing optimal formulations; and the approaches being used to improve the corneal penetration of a drug molecule and delay its elimination from the eye. The focus of this review is on the recent developments in topical ocular drug delivery systems, the rationale for their use, their drug release mechanism, and the characteristic advantages and limitations of each system. In addition, the review attempts to give various analytical procedures including the animal models and other models required for bioavailability and pharmacokinetic studies. The latter can aid in the design and predictive evaluation of newer delivery systems.

The dosage forms are divided into the ones which affect the precorneal parameters, and those that provide a controlled and continuous delivery to the pre- and intraocular tissues. The systems discussed include: (a) the commonly used dosage forms such as gels, viscosity imparting agents, ointments, and aqueous suspensions; (b) the newer concept of penetration enhancers, phase transition systems, use of cyclodextrins to increase solubility of various drugs, vesicular systems, and chemical delivery systems such as the prodrugs; (c) the developed and under-development controlled/continuous drug delivery systems including ocular inserts, collagen shields, ocular films, disposable contact lenses, and other new ophthalmic drug delivery systems; and (d) the newer trends directed towards a combination of drug delivery technologies for improving the therapeutic response of a non-efficacious drug. The fruitful resolution of the above-mentioned technological suggestions can result in a superior dosage form for both topical and intraocular ophthalmic application.     

Ocular preparations: the formulation approach

The main aim of pharmacotherapeutics is the attainment of an effective drug concentration at the intended site of action for a sufficient period of time to elicit the response. A major problem being faced in ocular therapeutics is the attainment of an optimal concentration at the site of action. Poor bioavailability of drugs from ocular dosage forms is mainly due to the tear production, non-productive absorption, transient residence time, and impermeability of corneal epithelium. This article reviews: [1] the barriers that decrease the bioavailability of an ophthalmic drug; [2] the objectives to be considered in producing optimal formulations; and [3] the approaches being used to improve the corneal penetration of a drug molecule and delay its elimination from the eye. The focus of this review is on the recent developments in topical ocular drug delivery systems, the rationale for their use, their drug release mechanism, and the characteristic advantages and limitations of each system. In addition, the review attempts to give various analytical procedures including the animal models and other models required for bioavailability and pharmacokinetic studies. The latter can aid in the design and predictive evaluation of newer delivery systems.

The dosage forms are divided into the ones which affect the precorneal parameters, and those that provide a controlled and continuous delivery to the pre- and intraocular tissues. The systems discussed include: (a) the commonly used dosage forms such as gels, viscosity imparting agents, ointments, and aqueous suspensions; (b) the newer concept of penetration enhancers, phase transition systems, use of cyclodextrins to increase solubility of various drugs, vesicular systems, and chemical delivery systems such as the prodrugs; (c) the developed and under-development controlled/continuous drug delivery systems including ocular inserts, collagen shields, ocular films, disposable contact lenses, and other new ophthalmic drug delivery systems; and (d) the newer trends directed towards a combination of drug delivery technologies for improving the therapeutic response of a non-efficacious drug. The fruitful resolution of the above-mentioned technological suggestions can result in a superior dosage form for both topical and intraocular ophthalmic application.     

The use of ultrasound and micelles in cancer treatment

The high toxicity of potent chemotherapeutic drugs like Doxorubicin (Dox) limits the therapeutic window in which they can be applied. This window can be expanded by controlling the drug delivery in both space and time such that non-targeted tissues are not adversely affected. Recent research has shown that ultrasound (US) can be used to control the release of Dox and other hydrophobic drugs from polymeric micelles in both time and space. It has also been shown using an in vivo rat tumor model that Dox activity can be enhanced by ultrasound in one region, while in an adjacent region there is little or no effect of the drug. In this article, we review the in vivo and in vitro research being conducted in the area of using ultrasound to enhance and target micellar drug delivery to cancerous tissues. Additionally, we summarize our previously published mathematical models that attempt to represent the release and re-encapsulation phenomena of Dox from Pluronic P105 micelles upon the application of ultrasound. The potential benefits of such controlled chemotherapy compels a thorough investigation of the role of ultrasound (US) and the mechanisms by which US accomplishes drug release and/or enhances drug potency. Therefore we will summarize our findings related to the mechanism involved in acoustically activated micellar drug delivery to tumors.     

Mesoporous silica as micro/nano-carrier: From passive to active cargo delivery,a mini review

Mesoporous silica has been widely explored for biomedical applications due to its unique structure and good biocompatibility. In particular it exhibits superior properties as micro/nano-carriers in the biomedical field. We explore their potentials in controlled drug/gene co-delivery and photodynamic therapy for cancer treatment both in vitro and in vivo. By incorporating mesoporous silica nanoparticles(MSNP) with two-dimensional nanomaterial, graphene oxide nano-sheet, we utilize MSNP in cellular bio-imaging with squaraine dye. Meanwhile, through delicate combination between mesoporous silica micro/nano carriers with catalytic/bio-catalytic reactions, we manage to achieve self-propelled micro/nano-motors based on mesoporous silica that are capable of transporting cargos in an active manner. Especially, enzyme powered mesoporous silica motors can be powered by physiologically available fuels such as glucose and urea,which are advantageous for future biomedical use. Motion control on both velocity and movement direction provides a powerful tool for targeted drug delivery. Therefore, such mesoporous silica based active carriers pave way to the solution of targeted drug delivery for cancer treatment in future nano-medicine field.     

磷酸钙微球骨修复材料研究进展

磷酸钙微球具有良好的渗透性、高的比表面积、低致密度和较好的力学性能,在分离、催化、传感、组织工程和药物释放等方面均有应用。本文综述了近年来磷酸钙陶瓷微球在组织工程和药物释放等骨修复相关领域的研究进展, 介绍了实心、多孔、空心和花瓣状等四种不同结构磷酸钙陶瓷微球制备方法以及在骨修复领域中的应用, 并归纳总结了各类微球具有的优缺点和改进的方向, 为骨修复用磷酸钙微球的设计和制备提供较系统的参考。     

Microemulsions as transdermal drug delivery systems for nonsteroidal anti-inflammatory drugs (NSAIDs): a literature review

Abstract

Pain is a global crisis and significant efforts have gone into the development of drugs that can be used to treat pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of analgesics that act to selectively relieve pain and inflammation without significantly altering consciousness. Although there have been many advancements with NSAIDs drug development; these drugs still present with severe adverse effects and toxicities, which often limits their use in many patients. Moreover, others are inadequate in relieving specific types of pain such as localized or nerve pain because of poor systemic absorption with conventional delivery systems. The topical route of drug delivery has been used to avoid many of these effects, but not without challenges of its own. The skin acts as an impermeable barrier to most polar drug candidate and absorption across the dermal membranes is often too slow and incomplete to produce meaningful therapeutic benefit. Nevertheless, the use of microemulsions as topical delivery systems for small molecule drug candidates like NSAIDs has been posited as a solution to this problem for years. This review focuses on the recent use of microemulsions as a probable solution to the challenges of transdermal drug delivery of NSAIDs and how microemulsions may be used to enhance the development of more effective but safer analgesic drug products for patients.     

The part mix and routing mix problem in FMS: a coupling between an LP model and a closed queueing network

In the near future many companies will face the problem of the optimal use of newly installed manufacturing technology (e.g. a flexible manufacturing system or FMS). Very often this will involve decisions on what parts to produce using the new system (the part mix problem) and how to produce these parts (the routing mix problem). We show that traditional operational research tools such as linear programming and queueing network theory are well suited to tackle these problems. In particular, LP models are combined with queueing network models in an iterative procedure. As such the strengths of both techniques can be exploited in making optimal use of the part mix and routing mix flexibility of the FMS.     

Buccal delivery systems

The oral cavity is an attractive site for drug delivery due to ease of administration and avoidance of possible drug degradation in gastrointestinal tract and first-pass metabolism. Buccal drug delivery specifically refers to the delivery of drugs within/through buccal mucosa to affect local/systemic pharmacological actions. This review briefly describes advantages and limitations of buccal drug delivery, anatomical structure of oral mucosa, and methodology in evaluating buccal drug delivery system, focusing on physiology, pharmacology, pathology, and formulation design in line with recent developments in buccal delivery systems.     

Novel strategies for the buccal delivery of macromolecules

For years now, the delivery of small molecules through the buccal mucosal route has been described in the literature, but it has only been over the past decade that investigations into macromolecule delivery via the buccal route have sharply increased. The administration of macromolecules such as proteins and peptides, antibodies, or nucleic acids by buccal administration would be greatly enhanced due to the avoidance of the gastrointestinal conditions, rapid uptake into systemic circulation, as well as the potential for controlled drug delivery. Since macromolecules are faced with a number of specific challenges related to permeation through the epithelium, several strategies have been employed historically to improve their buccal absorption and subsequent bioavailability. Several conventional strategies to improve macromolecule penetration include the use of chemical permeation enhancers, enzyme inhibitors and the use of mucoadhesive materials acting as carriers. More recent approaches include the incorporation of the macromolecule as part of nanostructured delivery systems to further enhance targeting and delivery. This review focuses on the different permeation enhancing strategies as well as formulation design that are tailored to meet the challenges of active macromolecule delivery using the buccal mucosal route of administration.